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RESUMEN
Se preparan derivados de triazoles condensados por 
reacción del producto de partida 4 con diversos reac-
tivos electrófilos. Las estructuras de todos los nuevos 
compuestos se establecen mediante análisis elemen-
tal y datos espectroscópicos. Todos los compuestos 
sintetizados se criban en busca de su actividad anti-
bacteriana. Los derivados de 1,2,4-triazol 4, 14 y 15 
exhiben una buena actividad antibacteriana respecto 
al antibiótico estándar Gentamicina. Se estudia el equi-
librio tautomérico entre las formas tiona y tiol de los 
compuestos 4 y 15 mediante cálculos mecanocuán-
ticos semiempíricos (AM1, MNDO y PM3) y ab initio 
(RHF/3-21G* y RHF/6-31G*) en fase gas.
 
Palabras clave: 1,2,4-triazoles, triazolo[3,4-b]tiadiaz-
oles, triazolo[3,4-b]tiadiazines, triazolo[3,4-b]tiadiaz-
epina, actividad antibacteriana. 
SUMMARY
Fused triazoles derivatives have been prepared from the 
reaction of the starting material 4 with some electrophilic 
reagents. The structures of all new compounds have been 
established on the basis of elemental analysis and spec-
troscopic data. All the synthesized compounds have been 
screened for their antibacterial activity. 1,2,4-Triazole de-
rivatives 4, 14 and 15 exhibited a good antibacterial activ-
ity compared with the standard antibiotic Gentamycin. The 
tautomeric equilibria of the compounds 4 and 15 thione 
and thiol form were studied by quantum chemical calcula-
tions semi-empirical (AM1, MNDO and PM3) and ab initio 
level (RHF/3-21G* and RHF/6-31G*) in the gas phase.
 
Keywords: 1,2,4-triazoles, triazolo[3,4-b]thiadiazoles, 
triazolo[3,4-b]thiadiazines, triazolo[3,4-b]thiadiazepine, 
antibacterial activity.
RESUM
Es preparen derivats de triazoles condensades per reacció 
del producte de partida 4 amb diversos reactius electròfils. 
Les estructures de tots els nous compostos s’estableixen 
mitjançant anàlisi elemental i dades espectroscòpiques. Tots 
els compostos sintetitzats es cribren cercant la seva activitat 
antibacteriana. Els derivats d’1,2,4-triazole 4, 14 i 15 exhi-
beixen una bona activitat antibacteriana respecte a l’antibiòtic 
estàndard Gentamicina. S’estudia l’equilibri tautomèric entre 
les formes tiona i tiol dels compostos 4 i 15 mitjançant càl-
culs mecanoquàntics semiempírics (AM1, MNDO i PM3) i ab 
initio (RHF/3-21G* i RHF/6-31G*) en fase gas.
 
Mots clau: 1,2,4-triazoles, triazolo[3,4-b]tiadiazoles, 
triazolo[3,4-b]tiadiazines, triazolo[3,4-b]tiadiazepina, ac-
tivitat antibacteriana.
INTRODUCTION
Fused 1,2,4-triazoles express antifungal, bactericidal,1-3 
anxiolytic,4,5 anticonvulsant6 and herbicidal7 activities or 
can act as antidepressants.8,9 The sulfonamide –SO2NH– 
group occurs in numerous biologically active compounds, 
which include antimicrobial drugs, saluretics, carbonic 
anhydrase inhibitors, insulin-releasing, antithyroid agents, 
antitumour drugs and number of other biological activi-
ties.10–17 Sulfonamides are among the most widely used 
antibacterial agents in the world, chiefly because of their 
low cost, low toxicity and excellent activity against com-
mon bacterial diseases18. Heterocyclic compounds con-
taining an amide group are used in the synthesis of bio-
logically substances19. This promoted us to synthesize a 
series of fused triazoles containing both the sulfonamide 
and the amide groups and characterized their structure by 
IR, 1H-NMR, and MS techniques to investigate their anti-
bacterial activities.
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RESULTS AND DISCUSSION
Sulfanilamide 1 was allowed to react with the succinic an-
hydride 2 under reflux the corresponding succinamic acid 
derivative  3 was afforded. Its IR spectrum showed bands 
at 3330-2750 (broad-COOH), 3320, 3280 (NH, NH2), 1750, 
1690 cm-1 (2 C=O). 1HNMR Spectrum revealed the follow-
ing signals at 2.4-2.7 (m, 4H, CH2CH2), 7.2 (s, 2H, NH2), 
10.2 (s, 1H, NH), 12.1ppm (br, 1H, OH). When compound 3 
was subjected to react with thiocarbohydrazide, three pos-
sible structures 4, 5 and 6 can be formulated (Scheme1). 
The structures 5 and 6 were discarded on the basis of ana-
lytical and spectral data. Infrared spectrum revealed the 
presence of absorption bands characteristic for NH, NH2 
(3390, 3260, 3220) and C=O (1700 cm-1). Mass spectrum 
of 4 showed a molecular ion peak at m/z 342 (M+; 13.03%) 
with a base peak at 56 (100%) and other significant peaks 
appeared at m/z 343 (M+1, 33.45%), 254 (13.03%), 185 
(41.55%) and other significant peaks appeared at m/z, 133 
(41.20%), 125 (88.87%), 101 (58.15%), 68 (44.01%).
The thiadiazole nucleus which incorporates N=C=S linkage 
exhibits a large number of biological activities20.  The reac-
tivity of compound 4 towards carboxylic acid derivatives 
was also investigated. Thus, refluxing of compound 4 in 
formic acid caused cyclization by elimination of two moles 
of water to give the triazolo[3,4-b]thiadiazole derivative 
7. The IR spectrum exhibited absorption bands at 3278, 
3104 (NH, NH2) and 1694 cm
-1 (C=O). Its mass spectrum 
revealed a molecular ion peak at m/z 352 (M+, 18.15%), 
with a base peak at m/z 88 (100%) and other significant 
peaks appeared at m/z 311 (28.57%), 262 (34.04%), 239 
(7.28%), 185 (3.34%), 134 (38.21%), 94 (82.82%).
Three possible structures 8, 9 and 10 can be formulat-
ed when compound 4 was refluxed in acetic anhydride. 
Structure 10 was established on the basis of analytical and 
spectral data. Its IR spectrum of 10 showed absorption 
bands at 3200 (NH), 1740, 1720, 1710, 1690 cm-1 (4 C=O). 
While, 1HNMR revealed signals at δ 2.6, 2.75, 2.82 (3s, 9H, 
3COCH3) and 14.2 (broad, 2H, 2 NH).
Compound 4 may exist  in two tautomeric forms, that is, 
as thione (NH) and the thiol (SH) forms, the first with a C=S 
double bond 4a, the latter having the endocyclic double 
bond C=N and the hydrogen atom transfer to the sulphur 
atom 4b (see Scheme 1). Molecular models of possible 
tautomeric forms were calculated in the gas phase, using 
semi-empirical AM1, PM3 and MNDO methods using Hy-
perChem 7.5 software. The initial geometries of the mol-
ecules were built means of standard parameters and then 
optimized by Polak-Ribiere geometrical optimization. The 
heat of formation and relative stabilities of the two tauto-
meric forms 4a and 4b are listed in Table 1.
Table 1. Heat of formation ( D 
o
fH ) and relative stabilities
( DD 
o
fH  kcal.mol-1) of tautomeric forms of 4a and 4b.
Method
D ofH DD ofH4a(Nh) 4b(Sh)
MNDO 172.81 159.59 -13.22
AM1 22.66 17.49 -5.17
PM3 26.20 18.03 -8.17
DD ofH =D
o
fH  (Sh) - D
o
fH  (Nh)
All semiempirical calculations lead to the same result that 
the thione-form has more heat of formation value than the 
thiol-form. The negative sign of the D D ofH  indicates that 
the thiol-form is more stable by all semi-empirical compu-
tational methods.
The equilibrium geometries have been calculated also 
by Ab initio calculations in the gas phase at HF/3-21G* 
and HF/6-31G* basis set level, were carried out using the 
GAUSSIAN 98 program.21 The optimized structures infor-
mation was shown in Fig. 1 along with their total energies 
at 3-21G* and 6-31G* (Hartree) and relative stability (in kcal 
mol-1). The data in Fig. 1 show that the relative energies 
of tantomers 4a and 4b obtained in HF/6-31G* and HF/3-
21G* calculation in gas phase differ significantly. Thus, 
while the HF/3-21G* data indicate preference for the thiol 
form. The HF/6-31G* data, on the other hand, indicate 
preference for the thione form.
The behavior of compound 4 towards some halogenated 
reagents was discussed herein. Thus, reaction of 4 with 
ethyl chloroacetate yielded the triazolo[3,4-b]thiadiazine 
derivative 11. The IR spectrum of 11 revealed absorption 
bands at 3362, 3260 (NH, NH2), 1722, 1704 cm
-1(2 C=O). 
1HNMR spectrum exhibited signals at 2.8 (m, 4H, 2 CH2), 
3.7 (s, 2H, SCH2), 7.5-7.8 (m, 6H, Ar-H + NH2) and 8.0 ppm 
(2s, 2H, 2NH).
On the other hand reaction of 4 with phenacyl bromide 
yielded the thioacetylbenzoyl derivative 12 rather than the 
triazolothiadiazine 13. Its IR spectrum showed the pres-
ence of absorption bands at 3362, 3260 (NH, NH2) and 
1720, 1702 cm-1 (2 C=O). 1HNMR spectrum exhibited the 
following signals at δ 2.7 (m, 4H, 2 CH2), 4.3 (s, 2H, SCH2), 
7.1-7.9 (m, 13H, Ar-H +NH2), 10.3 ppm (s, 1H, NH).
Compound 4 was treated with 2,3-dichloronaphthoqui-
none caused to furnish the corresponding triazolothiadi-
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azine derivative 14 through elimination of  two moles of 
HCl. Its IR spectrum showed absorption bands at 3412, 
3370, 3250 (NH, NH2), and 1690, 1666, 1654 cm
-1 (3 C=O). 
Mass spectrum revealed a molecular ion peak m/z 496 
(M+, 9.81%), with a base peak at 199 (100%) and other 
significant peaks were appeared at m/z 395 (8.05%), 341 
(25.25%), 265 (18.22%), 114 (52.14%), 92 (42.58%), 77 
(9.30%).
Also, the reactivity of the starting material 4 towards some 
carbonyl compounds was studied. Interaction of com-
pound 4 with p-chlorobenzaldehyde in acetic acid afford-
ed the Schiff’s base 15. IR spectrum revealed absorption 
bands at 3410, 3330, 3220 (NH, NH2), 1680 cm
-1 (C=O). 
1HNMR spectrum of 15 showed signals at δ 7.1-8.0 (, 11H, 
Ar-H + NH2 +N=CH), 10.0 (s, 1H, NH), 10.5, 13.9 (s, 1H, 
NH: SH-tautomer).
The thiol/thione tautomeric equilibrium were also carried 
out using semiempirical and ab initio molecular orbital 
methods. Thus, the tautomeric equilibrium involving thiol 
(SH) 15a or thione (NH) 15b forms. Similar trends were 
observed to the calculation above, which semiempirical 
calculations in gas phase indicate that the thiol form more 
stable (Table 2), whereas the HF/6-31G* calculation prefer-
ence for thione form (Fig. 2).       
 Table 2. Heat of formation (D
o
fH ) and rela-
tive stabilities (DD
o
fH  kcal.mol-1) of
tautomeric forms of 15a and 15b.
Method
D
o
fH D D ofH4a(NH) 4b(SH)
MNDO 162.10 149.96 -12.14
AM1 218.25 207.09 -11.16
PM3 43.56 31.64 -11.92
D D ofH =D
o
fH  (Sh) - D
o
fH  (Nh)
While, reaction of 4 with acetylacetone yielded triazole 17 
rather than the thiadiazole 16 on the basis of elemental 
analysis and spectral data. Also, reaction of 4 with cy-
clohexanone or 1,3-cyclohexanedione and/or demidone 
furnished the corresponding spiro compounds triazo-
lothiadiazole derivatives 18-20, respectively (Scheme 4). 
The IR spectrum of 17 showed absorption bands at 3362, 
3258 cm-1 (NH, NH2), 2924, 1716, 1700 cm
-1 (2 C=O). 
1HNMR spectrum revealed signals at 2.2, 2.6 (s, 6H, CH3, 
COCH3), 2.8 (m, 4H, 2 CH2), 4.3 ppm (s, 2H, CH2COCH3). 
Mass spectrum of 17 exhibited a molecular ion peak at 
Fig. 2 Optimized structures and atom numbering for the tautomric forms of thione (15a) and thiol (15b),
           proess obtained at the HF/6-31G* level
T hione T hiol
�E  = E (SH)- E (NH) = 17.75 kcal.mol-1
E = -2497.2260028 a.u. E = -2497.1977051 a.u.
Fig. 2 Optimized structures and atom numbering for the tautomric forms of thione (15a) and thiol (15b),
           proess obtained at the HF/6-31G* level
T hione T hiol
�E  = E (SH)- E (NH) = 17.75 kcal.mol-1
E = -2497.2260028 a.u. E = -2497.1977051 a.u.
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m/z 424 (M+; 16.88%) with a base peak at 99 (100%) and 
other significant peaks were observed at 362 (7.15%), 314 
(28.21%), 288 (8.38%), 217 (72.28%), 155 (70.18%), 111 
(63.78%), 73 (31.30%). The IR spectrum of 18 revealed 
bands at 3310, 3280 (NH, NH2), 1710 cm
-1 (C=O). 1H-NMR 
spectrum of 18 exhibited signals at 1.9-2.2 (m, 10H, 5CH2-
cyclo), 5.4 (s, 2H, NH2), 7.0-7.8, 10.1, 10.2 (2s, 2H, 2NH). 
The IR spectrum of 19 showed bands at 3402, 3360 (NH, 
NH2), 1710, 1656 cm
-1(2C=O). Mass spectrum of com-
pound 19 revealed a molecular ion peak at m/z 436 (M+, 
0.38) with a base peak at 62 (100%) and other significant 
peaks appeared at 354 (3.58%), 320 (5.18%), 256 (6.48%), 
203 (5.56%), 181 (8.32%), 125 (8.88%), 84 (10.88%), 55 
(8.85%). IR spectrum of 20 showed bands at 3424, 3390 
(NH, NH2), 1693, 1650 cm
-1 (2C=O). Mass spectrum of 20 
exhibited a molecular ion peak at m/z 464 (M+; 1.78%) with 
a base peak at 126 (100%) and other significant peaks were 
appeared at m/z 421 (4.14%), 369 (7.64%), 359 (5.28%), 
269 (3.56%), 254 (54.71%), 172 (9.94%), 64 (38.33%).
The dicyanotriazolothiadiazole derivative 21 was obtained 
by reaction of 4 with [bis(methylsulfanyl)methylidene]ma-
lononitrile, via the elimination of two moles of methyl mer-
captan. The IR spectrum of 21 revealed bands at 3340, 
3186 (NH, NH2), 2202(C≡N), 1706 cm-1 (C=O). Its 1H-NMR 
spectrum exhibited signals at 2.7-2.9 (m, 4H, 2CH2), 7.2-
8.1 ppm (m, 8H, Ar-H+ NH2 + 2NH). Mass spectrum of 
compound 21 showed a molecular ion peak at m/z 416 
(M+ 5.23%), with a base peak at 73 (100%), and other sig-
nificant peaks were appeared at m/z 368 (17.48%), 288 
(18.80%), 238 (1.81%), 211 (18.88%), 149 (55.78%), 128 
(15.08%), 95 (28.03%), 58 (20.00%).
Finally, the triazolothiadiazepine derivative (22) was ob-
tained in good yield through reaction of 4 with ethoxym-
ethylenemalononitrile. Its IR spectrum showed bands at 
3350, 3270 (NH, NH2), 2210 (C≡N) and 1705 cm-1 (C=O). 
Mass spectrum of 22 revealed a molecular ion peak at m/z 
419 (M+; 8.47%) with base peak at 254 (100%) and other 
significant peaks were appeared at m/z 327 (11.50%), 288 
(1.34%), 199 (28.87%), 146 (47.88%), 118 (53.88%), 90 
(57.58%), 77 (13.50%).
BIOLOGICAL ACTIVITY
The results of the antibacterial studies are presented in Ta-
ble 1 revealed that the synthesized compound 4 containing 
mercapto, sulfonamide moieties and compound 14 which 
contains naphthoquinone and sulfonamide moieties, com-
pound 15 having mercapto, 4-chlorophenyl, sulfonamide 
moieties showed a promising activity equal that Gentamy-
cin. On the other hand, the tested compounds exhibited 
moderate antibacterial activities. From these results it can 
be concluded that biologically active compounds 4, 14 
and 15 (MIC values were 50 µg/mL) are nearly as active as 
the standard antibiotic Gentamycin.
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ExPERIMENTAL
All m.p.s are uncorrected. Elemental analyses were car-
ried out at the microanalytical laboratories of the faculty 
of Science, Cairo University. The IR spectra (KBr) were 
measured on a Shimadzu IR 110 spectrometer, 1H-NMR 
spectra were obtained on a BRUKER proton NMR-Avance 
300 (300 MHz), in DMSO-d6 as a solvent, using tetrameth-
ylsilane (TMS) as internal standard. Mass spectra were run 
on HP Model MS.5988.
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Compd.
No.
Eschericha coli
(NCTC 5933)
Serratia marcescens
(IMRU-70)
Staphylococ-
cus aureus
(NCTC-7447)
Bacillus cereus
(ATCC-14579)
Diameter
(m m)
MIC
(µg/mL-1)
Diameter
(m m)
MIC
(µg/mL-1)
Diameter
(m m)
MIC
(µg/mL-1)
Diameter
(m m)
MIC
(µg/mL-1)
4 26 60 24 70 28 50 26 60
7 20 80 20 80 24 70 18 90
10 18 90 20 80 20 80 18 90
11 18 90 18 90 20 80 14 100
12 14 100 18 90 18 90 14 100
14 28 50 26 60 28 50 24 70
15 26 60 26 60 28 50 24 70
17 20 80 14 100 24 70 14 100
18 20 80 20 80 24 70 18 90
19 20 80 18 90 22 65 20 80
20 18 90 20 80 20 80 20 80
21 18 90 20 80 20 80 20 80
22 14 100 18 90 20 80 18 90
DMF - - - - - - - -
Gentamycin 28 - 27 - 30 - 25 -
TABLE 1: Antibacterial of the synthesized compounds. 
N-(4-sulfamoyl-phenyl)-succinamic acid  3.
A mixture of sulfanilamide (0.01 mol) and succinic anhy-
dride (0.01 mol) in ethanol (30 ml) containing 3 drops of 
triethylamine was refluxed for 3hr. the obtained solid was 
recrystallized from ethanol to give (3, Table 2).
3-(4-Amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-n-(4-
sulfamoyl-phenyl)-propion- amide  4.
A mixture of 3 (0.01 mol) and thiocarbohydrazide (0.01 
mol) was fused at 220ºC in an oil bath for 15 min. After 
cooling the reaction mixture was triturated with ethanol to 
give (4, Table 2).
n-(4-Sulfamoyl-phenyl)-3-[1,2,4]triazolo[3,4-b]
[1,3,4]-thiadiazol-3-yl-propionamide    7.
A solution of 4 (0.01 mol) in formic acid (10 ml) was re-
fluxed for 6hr. the obtained solid was recrystallized from 
dioxane to give (7, Table 2).
3-(1-Acetyl-4-acetylamino-5-thioxo-4,5-dihydro-
1H-[1,2,4]triazol-3-yl)-n-(4-acetyl- sulfamoyl-phenyl)-
propionamide   10
A solution of 4 (0.01 mol) in acetic anhydride (20 ml) was 
heated under reflux for 10 hr. After the solution had cooled, 
the excess acetic anhydride was removed under reduced 
pressure. The obtained solid was recrystallized from etha-
nol to give (10, Table 2).
3-(6-Oxo-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b]
[1,3,4]-thiadiazin-3-yl)-n-(4 sulfamoyl -phenyl)-propi-
onamide  11.
To a solution of 4 (0.01 mol) in dioxane (50 ml) and trieth-
ylamine (0.01 mol), ethyl chloroacetate (0.01 mol) was add-
ed. The reaction mixture was refluxed for 2 hrs. The pre-
cipitate that had formed was filtered off, washed with water, 
dried and recrystallized from dioxane to give (11, Table 2).
3-[4-Amino-5-(2-oxo-2-phenyl-ethylsulfanyl )-
4H-[1,2,4]triazol-3-yl]-n-(4-sulfamoyl-phenyl)-propi-
onamide 12.
A mixture of 4 (0.01 mol) and phenacyl bromide (0.01 
mol) in dimethylformamide (10 ml) containing triethylam-
ine (0.01 mol) was refluxed for 8 hrs. The solid that had 
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formed was collected and crystallized from ethanol to give 
(12, table 2).
3-(5,10-Dioxo-5,10-dihydro-4h-11-thia-1,2,3a,4-tet-
raaza-cyclopenta[b]anthracen-3-yl)-N-(4-sulfamoyl-
phenyl)-propionamide  14.
A mixture of 4 (0.01 mol) and 2,3-dichloronaphthoquinoine 
(0.01 mol) in dimethylformamide (10 ml) containing (0.01 
mol) triethylamine was refluxed for 12 hr. the solid obtained 
was recrystallized from dioxane to give (14, Table 2).
3.9. Synthesis of 3-{4-[(4-Chloro-benzylidene)-amino]-
5-mercapto-4h-[1,2,4]triazol-3-yl}-N-(4-sulfamoyl-
phenyl)-propionamide  15.
A mixture of 4 (0.01 mol) and 4-chlorobenzaldehyde (0.01 
mol) in glacial acetic acid (10 ml) was refluxed for 3hr. the 
solvent was evaporated under reduced pressure, and the 
solid product was collected and recrystallized from acetic 
acid to give   (15, Table 2).
3-[5-Mercapto-4-(1-methyl-3-oxo-butylideneamino)-
4H-[1,2,4]triazol-3-yl]-n-(4sulfa moyl-phenyl)-
propionamide 17,  18, 19, 20, 3-(6-Dicyanom-
ethylene-5,6-dihydro-[1,2,4]triazolo[3,4-b][1,3,4]
thiadiazol-3-yl)-n-(4-sulfamoyl-phenyl)-propion- amide 
21,  3-(8-Amino-7-cyano-[1,2,4]triazolo[3,4-b][1,3,4]thi-
adiazepin-3-yl)-n-(4-sulfamoyl-phenyl)-propionamide 
22.
A mixture of 4 (0.01 mol) acetylacetone or cyclohexanone or 
1,3-cyclohexanedione or demidone or [bis(methylsulfanyl)
methylidene]-malononitrile and / or ethoxymethylenemalono-
nitrile (0.01 mol) and triethyl-amine (0.01 mol) in dimethylfor-
mamide (20 ml) was refluxed for 12 hr. the obtained solid was 
recrystallized from DMF/H2O to give compounds 17,18-22, 
respectively (Table 2).
MICROBIOLOGY
All the test compounds were assayed in vitro for antibacte-
rial activity against two different strains of Gram-negative 
[Escherichia coli (NCTC 5933) and Staphylococcus aureus 
(NCTC 7447)] and Gram-positive [Serratia marcescens 
(IMRU 70) and Bacillus subtilis (ATCC 14579)] .The anti-
bacterial activity of the compounds was determined by the 
agar diffusion technique22. A 1 mg mL-1 solution in dimeth-
ylformamide was used. The bacteria was maintained on 
nutrient agar media. DMF showed no inhibition zones. The 
agar media was incoubated with different microorganism 
culture tested. After 24h of incubation at 30oC for bacteria, 
the diameter of the inhibition zone (m m) was measured. 
Gentamycin in a concentration of 0.2 mg/mL was used as 
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Compd. M.P. Yield Mol. Formula Required (found)
No. (oC) (%) (M.wt) C h N
3 208-10 81
C10H12N2O5S  
(272)
44.12
44.40
4.41
4.60
10.29
10.40
4 258-60 84
C11H14N6O3S2
(342)
38.60
38.30
4.59
4.30
24.56
24.80
7 >300 75
C12H12N6O3S2
(352)
40.91
40.60
3.41
3.10
23.86
23.60
10 176-78 68
C17H20N6O6S2
(468)
43.59
43.20
4.27
4.40
17.95
17.70
11 291-93 79
C13H14N6O4S2
(382)
40.84
40.50
3.66
3.80
21.99
21.70
12 226-28 71
C19H20N6O4S2
(460)
49.57
49.70
4.35
4.60
18.26
18.50
14 >300 65
C21H16N6O5S2
(496)
50.81
50.60
3.23
3.50
16.94
16.70
15 253-55 62
C18H17N6O3S2Cl
(464.5)
46.50
46.30
3.66
3.40
18.08
18.30
17 290-92 73
C16H20N6O4S2
(424)
45.28
45.40
4.72
4.50
19.81
19.60
18 >300 68
C17H20N6O3S2
(420)
48.57
48.30
4.76
4.90
20.00
20.20
19 >300 63
C17H20N6O4S2
(436)
46.79
46.90
4.59
4.70
19.27
19.50
20 >300 61
C19H24N6O4S2
(464)
46.15
46.30
5.17
5.30
18.10
18.30
21 270-72 76
C15H12N8O3S2
(416)
43.27
43.50
2.88
3.10
26.92
26.70
22 292-94 70
C15H14N8O3S2
(418)
43.06
43.20
3.35
3.10
26.79
26.60
Table 2: Characterization data of newly synthesized compounds.
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Compd. No. IR (KBr, cm-1) 1hNMR (ppm, δ) (DMSO-d6)
3 3330-2750(br-COOh), 3320, 3280 (Nh,Nh2), 2940 (Ch-aliph), 1750, 1690 (2C=O), 2.7(m, 4h, 2xCh2), 7.2(s, 2h, Nh2), 7.4-7.9(m, 4h, 
Ar-h), 10.2(s, 1h, Nh), 12.1(br, 1h, COOh)
4 3390, 3260, 3220 (Nh, Nh2), 2940 (Ch-aliph.), 1700 (C=O), 1620 (C=N). 2.8 (m, 4h, 2 Ch2), 7.3-7.6 (m, 4h, Ar-h), 7.8 
(br, 4h, 2 Nh2), 8.3 (s, 2h, 2 Nh).
7 3278, 3104 cm-1 (Nh, Nh2), 3054 (Ch-arom.), 2924, 2854 
(Ch-aliph.), 1694 (C=O), 1582 cm-1 (C=N).
10 3200(Nh), 2926 (Ch-aliph.), 1740, 1720, 1710, 1690 (4 C=O), 1630 cm-1 (C=N). 2.2 (m, 4h, 2 Ch2), 2.6, 2.75, 2.82 (3s, 9h, 3COCh3), 
7.2-8.5 (m, 4h, Ar-h), 14.2 (s, 2h, 2 Nh).
11 3362, 3260 (Nh, Nh2), 3094 (Ch-arom.), 2944 (Ch-
aliph.), 1722,1704 (2C=O),1598  (C=N).
2.7 (m, 4h, 2 Ch2), 4.3 (s, 2h, SCh2), 7.1-7.9 
(m, 13h, Ar-h +Nh2), 10.3 (s, 1h, Nh).
12 3362, 3260 (Nh, Nh2), 2926, 2854 (Ch-aliph.), 1720, 1702 cm
-1 (2 C=O). 
14 3412, 3370, 3250 (Nh, Nh2), 2924 (Ch-aliph.), 1690, 
1666, 1654 (3 C=O), 1600 cm-1 (C=N).
2.4 (m, 4h, 2 Ch2), 7.1-8.0 (, 11h, Ar-h+ Nh2+N=Ch), 
10.0 (s, 1h, Nh), 10.5, 13.9 (s, 1h, Nh:Sh-tautomer).
15 3410, 3330, 3220 (Nh, Nh2), 2950 (Ch-aliph.), 1680 (C=O), 1620 cm
-1 (C=N) 2.6 (s, 3h, COCh3), 2.8 (m, 4h, 2 Ch2), 4.3 (s, 2h, Ch-
2COCh3), 7.2-8.0 (m, 8h, Ar-h + Nh2 + 2Nh)
17 3362, 3258 (Nh, Nh2), 2924, 2854 (Ch-aliph.), 
1716, 1700 (2 C=O), 1598 cm-1 (C=N).
1.9-2.2 (m, 10h, 5Ch2-cyclo), 2.6 (m, 2Ch2), 5.4 (s, 2h, 
Nh2), 7.0-7.8 (m, 4h, Ar-h), 10.1,10.2 (2s, 2h, 2Nh).
18 3310, 3280 (Nh, Nh2), 2930  (Ch-aliph.), 1710 (C=O), 1620 cm
-1 (C=N).
19 3402, 3360 (Nh, Nh2), 2940 (Ch-aliph.),1710, 1656  (2C=O), 1592 cm
-1 (C=N).
20 3424, 3390 (Nh, Nh2), 2968 (Ch-aliph.),1693, 1650 (2C=O), 1590 cm
-1 (C=N)
21 3340, 3186(Nh, Nh2), 2924 (Ch-aliph.), 2202 (C≡N),1706  (C=O), 1620 cm-1 (C=N). 2.7-2.9 (m, 4h, 2Ch2), 7.2-8.1 (m, 8h, Ar-h+ Nh2 + 2Nh).
22 3350, 3270 (Nh,Nh2),2930  (Ch-aliph.),2210(C≡N), 1705 cm-1 (C=O).
Table 3: Spectroscopic data for the synthesized compounds 
a reference for antibacterial Activity. The minimal inhibitory 
concentration (MIC) of some of the test compounds was 
measured by a twofold serial dilution method23.
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